证券代码：000813 证券简称：德展健康 公告编号：2024-045 德展大健康股份有限公司 关于回购公司股份比例达到 1%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）分别于 2024 年 7 月 1 日及 2024 年 7 月 18 日召开了第八届董事会第二十七次会议和 2024 年第一次临时股 东大会，审议并通过了《关于回购公司股份方案的议案》。基于对公司所属行业 前景的认可、对公司未来发展的信心及公司价值的判断，为进一步增强投资者信 心，稳定投资者预期，维护广大投资者的利益，公司计划自股东大会审议通过之 日起 12 个月内使用不低于人民币 2 亿元，不超过人民币 3 亿元的自有资金，通 过集中竞价交易方式以不超过人民币 3.59 元/股的价格回购股份。本次回购的股 份将全部用于注销减少公司注册资本。具体内容详见公司于 2024 年 7 月 19 日在 《证券时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2024- ...

德展大健康股份有限公司（以下简称"公司"）分别于 2024 年 7 月 1 日及 2024 年 7 月 18 日召开了第八届董事会第二十七次会议和 2024 年第一次临时股东大 会，审议并通过了《关于回购公司股份方案的议案》。基于对公司所属行业前景 的认可、对公司未来发展的信心及公司价值的判断，为进一步增强投资者信心， 稳定投资者预期，维护广大投资者的利益，公司计划自股东大会审议通过之日起 12 个月内使用不低于人民币 2 亿元，不超过人民币 3 亿元的自有资金，通过集 中竞价交易方式以不超过人民币 3.59 元/股的价格回购股份。本次回购的股份将 全部用于注销减少公司注册资本。具体内容详见公司于 2024 年 7 月 19 日在《证 券时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2024-036）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在首次回购股份事实发生的次一交易 日予以公告。现将公司首次回购股份情况公告如下： 一、首次回购股份的具体情况 2024 ...

证券代码：000813 证券简称：德展健康 公告编号：2024－043 德展大健康股份有限公司 关于公司诉讼事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼（仲裁）阶段：案件一已完成首次开庭，案件二尚未开 庭 2、上市公司所处的当事人地位：被告 3、涉案的金额：可能金额约为 7 亿元 4、对上市公司损益产生的影响：暂无法准确地判断对公司本期利润或期后 利润的影响。 近日，德展大健康股份有限公司（以下简称"德展健康""公司"）通过公 开渠道了解，并主动与相关法院沟通确认，根据最新收到的两起公司相关诉讼资 料。现将有关具体情况公告如下： 一、案件的基本情况 （一）案件一的基本情况 因公司原控股股东美林控股集团有限公司（以下简称"美林控股"）与广州 融晟投资发展有限公司（以下简称"广州融晟"）之间的合同纠纷，广州融晟将 公司作为被告之一向广州市中级人民法院提起诉讼申请（以下简称"案件一"）。 原告：广州融晟投资发展有限公司 被告一：美林控股集团有限公司 被告二：德展金投集团有限公司（以下简称"德展金投"） 被告三：张湧 被告 ...

证券代码：000813 证券简称：德展健康 公告编号：2024-041 德展大健康股份有限公司 第八届董事会第二十八次会议决议公告 三、备查文件 1、德展大健康股份有限公司第八届董事会第二十八次会议决议。 本公司及其董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 德展大健康股份有限公司（以下简称"公司"）第八届董事会第二十八次会 议的通知已于 2024 年 8 月 23 日以电子邮件方式发出；公司于 2024 年 8 月 27 日 10:00 以通讯表决方式召开。本次会议应参加会议董事 9 人，实际参加会议董事 9 人。会议由董事长魏哲明先生主持，公司全部监事及高管列席了本次会议。本 次会议的召集、召开符合《公司法》及《公司章程》的规定。 二、董事会会议审议情况 1、关于公司 2024 年半年度报告全文及摘要的议案 公司依据 2024 年上半年生产经营情况编制了《德展大健康股份有限公司 2024 年半年度报告》《德展大健康股份有限公司 2024 年半年度报告摘要》。2024 年上半年公司实现营业收入 2.48 亿元，同比增长 12.46%，实现 ...

| | 海南德澄健康 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 医疗有限责任 | 子公司 | 其他应收款 | 2,400.00 | 2,800.00 | - | - | 5,200.00 | 往来款 | 非经营性往来 | | | 公司 | | | | | | | | | | | | 德展大健康产 业有限公司 | 子公司 | 其他应收款 | 330.75 | - | - | - | 330.75 | 往来款 | 非经营性往来 | | | 汉萃（天津） 生物技术股份 有限公司 | 子公司 | 其他应收款 | 105.16 | 152.31 | - | - | 257.47 | 往来款 | 非经营性往来 | | | 北京红惠新医 药科技有限公 | 子公司 | 其他应收款 | - | 500.00 | - | - | 500.00 | 往来款 | 非经营性往来 | | | 司 | | | | | | | | | | | 小计 | —— | —— | —— | 15,174.35 ...

证券代码：000813 证券简称：德展健康 公告编号：2024-042 德展大健康股份有限公司 1、关于公司 2024 年半年度报告全文及摘要的议案 公司依据 2024 年上半年生产经营情况编制了《德展大健康股份有限公司 2024 年半年度报告》《德展大健康股份有限公司 2024 年半年度报告摘要》。2024 年上半年公司实现营业收入 2.48 亿元，同比增长 12.46%，实现归属上市公司股 东净利润 1,015.26 万元，同比增长 234.22%。 监事会审核意见：本报告期，公司监事会本着对全体股东负责的精神，对公 司 2024 年半年度报告进行了认真的审查，认为公司董事会编制和审议公司 2024 年半年度报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、 准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 表决结果：同意 4 票，反对 0 票，弃权 0 票。 第八届监事会第十七次会议决议公告 本公司及其监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 德展大健康股份有限公司（以下简称"公司"） ...

2、本次计提资产减值准备的资产范围、总金额、拟计入的报告期间 本次计提资产减值准备计入的报告期间为 2024 年 1 月 1 日至 2024 年 6 月 30 日。经过对 2024 年 6 月 30 日存在可能发生减值迹象的资产进行清查和减值 测试后，计提 2024 年半年度各项资产减值准备 1,044.25 万元，明细如下表： 证券代码：000813 证券简称：德展健康 公告编号：2024－038 德展大健康股份有限公司 关于 2024 年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）根据《深圳证券交易所股票 上市规则（2024 年修订）》《企业会计准则》以及公司会计政策等相关规定，对可 能发生资产减值损失的资产计提减值准备。现将具体情况公告如下： 一、本次计提减值准备情况概述 1、本次计提资产减值准备的原因 根据《企业会计准则》及公司会计政策规定，公司对母公司及下属所有子公 司截至 2024 年 6 月 30 日的各类资产进行了全面清查盘点和分析，认为资产中应 收账款、其他应收款、存 ...

证券代码：000813 证券简称：德展健康 公告编号：2024－039 德展大健康股份有限公司 关于美林控股业绩承诺补偿履行情况进展暨 凯迪投资提起仲裁的公告 股东新疆凯迪投资有限责任公司保证向本公司提供的信息披露内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、业绩承诺基本情况 2021 年 5 月 13 日，德展大健康股份有限公司（以下简称"德展健康"、"公 司"）原控股股东美林控股集团有限公司（以下简称"美林控股"）等与新疆凯迪 投资有限责任公司（以下简称"凯迪投资"）签署了《股份转让协议》，转让美林 控股及相关方所持部分德展健康股份并转让控制权，在转让协议中美林控股承诺 德展健康在业绩承诺期间（2021-2023 年度）累计实现归母净利润不低于人民币 12.4亿元。若德展健康2021-2023年度累计实现归母净利润数低于12.4亿元的， 则美林控股同意以现金或现金等价物向德展健康支付累计实现归母净利润数与 累计承诺净利润数 12.4 亿元之间的差额部分。约定的现金补偿款或现金等价物 应在德展健康 2023 年度审计报告 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥248,317,627.03, representing a 12.46% increase compared to ¥220,809,774.68 in the same period last year[12]. - The net profit attributable to shareholders of the listed company was ¥10,152,636.38, a significant turnaround from a loss of ¥7,564,371.15, marking a 234.22% improvement[12]. - The basic earnings per share increased to ¥0.0047 from a loss of ¥0.0034, reflecting a 238.24% growth[12]. - The total assets at the end of the reporting period were ¥5,365,254,359.93, a slight decrease of 0.25% from ¥5,378,612,557.62 at the end of the previous year[12]. - The net assets attributable to shareholders of the listed company were ¥5,240,846,693.12, showing a marginal increase of 0.06% from ¥5,237,902,679.94[12]. - The net cash flow from operating activities was ¥7,902,115.84, a significant recovery from a negative cash flow of ¥8,834,774.56, representing a 189.44% improvement[12]. - The weighted average return on net assets was 0.19%, an increase of 0.33% compared to the previous year's -0.14%[12]. - The company's total revenue for the reporting period was ¥248,317,627.03, representing a year-on-year increase of 12.46% compared to ¥220,809,774.68 in the same period last year[41]. - The revenue from the pharmaceutical sector was ¥246,815,643.48, accounting for 99.40% of total revenue, with a year-on-year growth of 19.61%[42]. - The company's gross profit margin in the pharmaceutical sector improved to 61.04%, up by 1.13% from the previous year[43]. Business Strategy and Market Focus - The company is focused on future development strategies and market expansion, although specific details were not disclosed in the report[2]. - The main business of the company focuses on the research, production, and sales of pharmaceuticals, particularly cardiovascular drugs, with key products including Atorvastatin Calcium Tablets and Amlodipine Atorvastatin Calcium Tablets[16]. - The company has expanded into new business areas such as biopolypeptides and medical services, with products like "Musuyan" medical cold compress and "Ruyinfangxing" series hangover relief peptides[16]. - The marketing model for the pharmaceutical business remains a combination of distributors and promoters, with a production model based on sales forecasts[17]. - The company emphasizes innovation in drug development, focusing on cardiovascular, oncology, and metabolic diseases, with a strategy of both independent and collaborative development[17]. - The company aims to reduce the premature mortality rate from cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes among the population aged 30-70 by 20% compared to 2015 levels by 2025[24]. - The company is actively expanding its market coverage and brand influence by leveraging policy advantages from national procurement initiatives[24]. - The company is focusing on a transition from a disease-centered approach to a health-centered approach, aligning with national health strategies[24]. Research and Development - The company is enhancing its R&D capabilities, with a focus on two innovative cardiovascular drugs that are making significant progress[33]. - The WYY project has completed preliminary research in the first half of 2024 and will begin toxicology batch and clinical trial product GMP preparation in the second half[34]. - The company has filed 26 patents during the reporting period, with a total of over 130 authorized patents and nearly 40 software copyrights as of the end of the reporting period[34]. - The company has successfully launched new products, including Amlodipine Atorvastatin Tablets (Nile) and Trimetazidine Hydrochloride Tablets, expanding its product matrix[24]. Environmental Responsibility - The company strictly adheres to multiple environmental protection laws and regulations, including the Environmental Protection Law of the People's Republic of China and the Solid Waste Pollution Prevention Law[65]. - The company has obtained various environmental approvals for its subsidiaries, including a valid pollution discharge permit for Beijing Jialin Pharmaceutical Co., effective from June 12, 2024, to June 11, 2029[68]. - The company operates in compliance with industry emission standards and has established measures for pollution control[67]. - The company has a focus on environmental responsibility, as indicated by its commitment to various environmental laws and standards[66]. - The company is actively monitoring and managing its environmental impact through stringent waste and emission controls[73]. - The company reported a total of 1.5 mg/L for ammonia nitrogen (NH3-N) in wastewater discharge, adhering to the standard DB11/307-2013[71]. - The company achieved a total phosphorus level of 0.3 mg/L in wastewater discharge, complying with the DB11/307-2013 standard[71]. - The company reported a maximum particulate matter emission of 5.0 mg/Nm³, complying with the DB11/139-2015 standard[70]. Legal and Compliance Issues - The company is involved in a contract dispute with Dai Yanzhen, with a claim amounting to ¥47,778.24 thousand, and has applied for enforcement in August 2024[92]. - A civil lawsuit was filed against the company in December 2023 regarding a debt substitution claim, with the disputed amount being ¥3,087.25 thousand[93]. - The company has filed for enforcement against Dai Yanzhen for the return of RMB 428 million related to equity acquisition payments and corresponding penalties due to non-compliance[87]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[88]. - There were no violations regarding external guarantees during the reporting period[89]. - The semi-annual financial report has not been audited[90]. Shareholder and Equity Information - The major shareholder, Meilin Holdings, reduced its stake in the company from 20% to 15% through various trading methods, amounting to a 5% reduction[103]. - Meilin Holdings' shares, totaling 315,379,600, representing 14.57% of its holdings, were subject to a court-ordered freeze as of March 20, 2024[103]. - The company plans to repurchase shares with a total amount not less than RMB 200 million and not exceeding RMB 300 million, to be used for cancellation[104]. - The company completed a capital increase of RMB 32.13 million in its subsidiary, reducing its ownership from 60% to 49.42%, which will no longer be included in the consolidated financial statements[105]. - The company acquired the remaining 40% equity of Hainan Dezheng, making it a wholly-owned subsidiary, to enhance its business layout[106]. Financial Position and Liabilities - The company's debt totaled 137.43 million yuan, with an asset-liability ratio of 2.56%, indicating a low level of indebtedness[32]. - The total liabilities increased from CNY 137,145,270.06 to CNY 137,426,368.73, an increase of about 0.21%[119]. - The company's tax payable increased from CNY 3,434,736.10 to CNY 8,194,397.51, an increase of approximately 138.5%[119]. - The company recognized an asset impairment provision of RMB 34.56 million for accounts receivable, other receivables, and inventory due to signs of impairment[104]. Operational Efficiency - The company has maintained its operational model without significant changes during the reporting period[17]. - The company has restored production for several existing products, including Warfarin Sodium Tablets, to enhance its product offerings[24]. - The company has increased its brand visibility through strategic collaborations and educational events with major retail pharmacies, aiming to enhance customer loyalty and sales[24]. Market Trends and Challenges - The cardiovascular drug market in China saw a slight decline of 1.30% in sales, reaching approximately 16.4 billion yuan in 2023 compared to 2022[28]. - The retail drug market in China experienced a year-on-year increase of 0.60% in Q1 2024, with cardiovascular drugs accounting for 8.00% of the total market[30]. - The company faces risks from rising production costs due to increases in raw material prices and logistics costs, and it aims to control these costs through supplier management and production technology innovation[59].

证券代码：000813 证券简称：德展健康 公告编号：2024－037 德展大健康股份有限公司 2020 年 3 月 23 日，德展大健康股份有限公司（以下简称"公司"）与戴彦 榛、北京长江脉医药科技有限责任公司（以下简称"长江脉"）在北京市朝阳区 签署《德展大健康股份有限公司、戴彦榛、北京长江脉医药科技有限责任公司共 同签署的投资协议》（以下简称"《原协议》"），收购戴彦榛持有的长江脉 70% 股权，交易价格为 7.7 亿元，并分期向戴彦榛支付了股权转让价款 4.3 亿元，后 续款项因戴彦榛个人原因，经各方协商一致暂缓支付。 2021 年 4 月 20 日，因戴彦榛违约，公司与戴彦榛及长江脉签署了《德展大 健康股份有限公司、戴彦榛、北京长江脉医药科技有限责任公司共同签署的投资 协议之解除协议》（以下简称"《解除协议》"），各方协商一致解除《原协议》， 戴彦榛于协议签署后 6 个月内返还 4.3 亿元股权收购款，其中 1,000 万元应于 《解除协议》生效后 20 日内支付，剩余款项及其需向公司支付的违约金 4,300 万元应于 2021 年 10 月 19 日前支付。公司于 2021 年 5 月 13 日收 ...